R&D Pipeline

Our Pipeline and Its Potential

Beyond Air Pipeline & Market Size

Product Indication Development
Status
Key Dates(1) US Sales
Potential(2)
Worldwide Sales
Potential(2)
LungFitPH
(Pulmonary Hypertension)
In-Hospital use for PPHN and cardiac surgery Final preparations for PMA submission FDA PMA filing 2Q20

US Launch 4Q20
>$300m >$600m
LungFit COVID-19 Pre-Clinical Initiate US COVID-19 treatment study pending FDA approvals N/A N/A
LungFit Bronchiolitis Pivotal Phase Pivotal Starts 4Q21

US Launch 2023
>$500m

Beyond Air to commercialize
>$1.2b
LungFit Home Nontuberculous mycobacteria (NTM) lung infection Pilot phase Q20 start for at-home pilot study with self-administration >$1b >$2.5b
LungFit Home Severe exacerbations due to lung infections in COPD patients Pre-clinical Pilot study start 2021 >$2.5b >$6b
Solid Tumors Multiple solid tumors Pre-clinical Initial data 2Q20 TBD TBD

†Caution - LungFit is an Investigational Device, Limited by Federal (or United States) Law to Investigational Use.

(1) All dates are based on projections and appropriate financing, anticipated first launch on a global basis pending appropriate regulatory approvals

(2) All figures are Company estimates for peak year sales: Global sales potential includes US sales potential

Important Safety Information

Caution - LungFit is an Investigational Device, Limited by Federal (or United States) Law to Investigational Use.